Phenylacetylglutamine as a novel biomarker of type 2 diabetes with distal symmetric polyneuropathy by metabolomics.

J Endocrinol Invest · 2023 · PMC10105673 · PMID 36282471

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

1 b), 6 of which showed an increasing trend among the three groups and were identified as differential metabolites of DSPN (Fig. 2 c).

also in 63,971 other papers

showed a trendno p-value reported

Looking across above pathways, we found that the upstream substances of PAG, phenylacetate, and phenylpyruvate were showed a trend of upregulation in the DSPN group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.